Abiopharma

New Form 4 - Tarsus Pharmaceuticals, Inc. Filed: 2025-06-16 AccNo: 0001819790-25-000091 Size: 11 KB

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Streamline Health® Reports Fiscal First Quarter 2025 Financial Results

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

New Form 4 - Tarsus Pharmaceuticals, Inc. Filed: 2025-06-16 AccNo: 0001819790-25-000090 Size: 12 KB

New Form 144 - BeOne Medicines Ltd. Filed: 2025-06-16 AccNo: 0001950047-25-004317 Size: 5 KB

New Form 144 - Evolus, Inc. Filed: 2025-06-16 AccNo: 0001950047-25-004315 Size: 11 KB

New Form 4 - Tarsus Pharmaceuticals, Inc. Filed: 2025-06-16 AccNo: 0001819790-25-000088 Size: 12 KB

New Form 4 - TEVA PHARMACEUTICAL INDUSTRIES LTD Filed: 2025-06-16 AccNo: 0000950170-25-086697 Size: 5 KB

New Form 4 - Mineralys Therapeutics, Inc. Filed: 2025-06-16 AccNo: 0001933414-25-000067 Size: 8 KB

New Form 144 - DEXCOM INC Filed: 2025-06-16 AccNo: 0001969223-25-000433 Size: 4 KB

New Form 144 - GILEAD SCIENCES, INC. Filed: 2025-06-16 AccNo: 0001950047-25-004309 Size: 12 KB

New Form 8-K - Longeveron Inc. Filed: 2025-06-16 AccNo: 0001213900-25-054755 Size: 203 KB Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits

New Form SCHEDULE 13D/A - CureVac N.V. Filed: 2025-06-16 AccNo: 0001213900-25-054753 Size: 157 KB